AR035868A1 - Un acido nucleico recombinante que codifica una proteina de un peptido lider de lisozima de ave o equivalente funcional, un vector que lo comprende, una celula huesped, un metodo para producir una proteina de envoltura del hcv o una parte de la misma. - Google Patents
Un acido nucleico recombinante que codifica una proteina de un peptido lider de lisozima de ave o equivalente funcional, un vector que lo comprende, una celula huesped, un metodo para producir una proteina de envoltura del hcv o una parte de la misma.Info
- Publication number
- AR035868A1 AR035868A1 ARP020101494A ARP020101494A AR035868A1 AR 035868 A1 AR035868 A1 AR 035868A1 AR P020101494 A ARP020101494 A AR P020101494A AR P020101494 A ARP020101494 A AR P020101494A AR 035868 A1 AR035868 A1 AR 035868A1
- Authority
- AR
- Argentina
- Prior art keywords
- cell
- protein
- hcvis
- saccharomyces
- hcv envelope
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 6
- 108090000623 proteins and genes Proteins 0.000 title abstract 6
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 24
- 101710091045 Envelope protein Proteins 0.000 abstract 5
- 102000016943 Muramidase Human genes 0.000 abstract 5
- 108010014251 Muramidase Proteins 0.000 abstract 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 abstract 5
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 5
- 101710188315 Protein X Proteins 0.000 abstract 5
- 102100021696 Syncytin-1 Human genes 0.000 abstract 5
- 229960000274 lysozyme Drugs 0.000 abstract 5
- 235000010335 lysozyme Nutrition 0.000 abstract 5
- 239000004325 lysozyme Substances 0.000 abstract 5
- 241000235648 Pichia Species 0.000 abstract 3
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 3
- 241000235070 Saccharomyces Species 0.000 abstract 2
- 244000144977 poultry Species 0.000 abstract 2
- 241000228212 Aspergillus Species 0.000 abstract 1
- 108091026890 Coding region Proteins 0.000 abstract 1
- 241000235649 Kluyveromyces Species 0.000 abstract 1
- 241001138401 Kluyveromyces lactis Species 0.000 abstract 1
- 241000235058 Komagataella pastoris Species 0.000 abstract 1
- 241000235087 Lachancea kluyveri Species 0.000 abstract 1
- 241000221960 Neurospora Species 0.000 abstract 1
- 241000221961 Neurospora crassa Species 0.000 abstract 1
- 241000320412 Ogataea angusta Species 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 abstract 1
- 241000582914 Saccharomyces uvarum Species 0.000 abstract 1
- 241000235346 Schizosaccharomyces Species 0.000 abstract 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 abstract 1
- 241000311088 Schwanniomyces Species 0.000 abstract 1
- 241001123650 Schwanniomyces occidentalis Species 0.000 abstract 1
- 241000235013 Yarrowia Species 0.000 abstract 1
- 241000235015 Yarrowia lipolytica Species 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 210000005253 yeast cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24223—Virus like particles [VLP]
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Se relaciona con un ácido nucleico recombinante que comprende una secuencia de nucleótidos que codifica una proteína que comprende un péptido líder de lisozima de ave o un equivalente funcional del mismo, unido a una proteína de la envoltura de HCV o una parte de la misma, vectores, células huésped y métodos para la expresión eficaz de las proteínas de la envoltura del HCV en células eucarióticas. Más en particular, dichos vectores comprenden la secuencia codificadora para un péptido de senal de lisozima de ave o un equivalente funcional del mismo, unido a una proteína de la envoltura de HCV o una parte de la misma. Dicho péptido de senal de lisozima de ave es removido de manera eficaz cuando la proteína que comprende dicho péptido de senal de lisozima de ave unido a una proteína de la envoltura del HCV o una parte de la misma, es expresado en una célula eucariótica. Las células eucarióticas adecuadas incluyen células de la levadura tales como las células de Saccharomyces o Hansenula. Reivindicación 2: El ácido nucleico recombinante de acuerdo con la reivindicación 1, en el cual dicha proteína está caracterizada por la estructura CL-[(A1)a- (PS1)b - (A2)c]-HCVENV - [(A3)d - (PS2)e - (A4)f] en la cual: CL es un péptido líder de lisozima de ave o un equivalente funcional del mismo; A1, A2, A3 y A4 son péptidos adaptadores que pueden ser iguales o diferentes, PS1 y PS2 son sitios de procesamiento que pueden ser iguales o diferentes; HCVENV es una proteína de la envoltura del HCV o una parte de la misma; a, b, c, d, e, y f son 0 o 1; y en la cual de manera opcional A1 y/o A2 son parte de PS1 y/o en la cual A3 y/o A4 son parte de PS2. Reivindicación 3: Los ácidos recombinantes de acuerdo con la reivindicación 1 o la reivindicación 2, que comprenden además elementos reguladores que permiten la expresión de dicha proteína en una célula huésped eucariótica. Reivindicación 20: La célula huésped de acuerdo con la reivindicación 19, que es una célula de Saccharomyces, tal como una célula de Saccharomyces cerevisiae, una célula de Saccharomyces kluyveri o una célula de Saccharomyces uvarum, una célula de Schizosaccharomyces, tal como una célula de Schizosaccharomyces pombe, una célula de Kluyveromyces, tal como una célula de Kluyveromyces lactis, una célula de Yarrowia, tal como una célula de Yarrowia lipolytica, una célula de Hansenula, tal como una célula de Hansenula polymorpha, una célula de Pichia, tal como una célula de Pichia pastoris, una célula de Aspergillus, una célula de Neurospora, tal como una célula de Neurospora crassa, o una célula de Schwanniomyces, tal como una célula de Schwanniomyces occidentalis, o una célula mutante derivada de cualquiera de las mismas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01870088 | 2001-04-24 | ||
| US30560401P | 2001-07-17 | 2001-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035868A1 true AR035868A1 (es) | 2004-07-21 |
Family
ID=34072546
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101493A AR035867A1 (es) | 2001-04-24 | 2002-04-24 | Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e |
| ARP020101494A AR035868A1 (es) | 2001-04-24 | 2002-04-24 | Un acido nucleico recombinante que codifica una proteina de un peptido lider de lisozima de ave o equivalente funcional, un vector que lo comprende, una celula huesped, un metodo para producir una proteina de envoltura del hcv o una parte de la misma. |
| ARP020101495A AR035869A1 (es) | 2001-04-24 | 2002-04-24 | Proteinas de la envoltura de hcv glicosiladas en la estructura central, un metodo para producir la proteina de envoltura de hcv aislada, una composicion que la comprende, metodo para detectar la presencia de anticuerpos anti-hcv en una muestra, un kit de diagnostico para detectar la presencia de ant |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101493A AR035867A1 (es) | 2001-04-24 | 2002-04-24 | Una particula semejante a un virus hcv formada por una proteina de envoltura de hcv, un metodo para formar dicha particula, un medicamento que la contiene, una vacuna, un metodo de deteccion, un kit de diagnostico, el uso de cepas de hansenula o saccharomyces para la expresion de una proteina hcv, e |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101495A AR035869A1 (es) | 2001-04-24 | 2002-04-24 | Proteinas de la envoltura de hcv glicosiladas en la estructura central, un metodo para producir la proteina de envoltura de hcv aislada, una composicion que la comprende, metodo para detectar la presencia de anticuerpos anti-hcv en una muestra, un kit de diagnostico para detectar la presencia de ant |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US7314925B2 (es) |
| EP (3) | EP1381671A2 (es) |
| JP (2) | JP4261195B2 (es) |
| KR (1) | KR100950104B1 (es) |
| CN (1) | CN1636050A (es) |
| AR (3) | AR035867A1 (es) |
| AU (3) | AU2002257392B2 (es) |
| BR (2) | BR0209034A (es) |
| CA (3) | CA2443781A1 (es) |
| CZ (1) | CZ20032853A3 (es) |
| HU (1) | HUP0303924A2 (es) |
| MX (2) | MXPA03009632A (es) |
| NZ (2) | NZ529019A (es) |
| OA (1) | OA13092A (es) |
| PL (1) | PL366621A1 (es) |
| RU (1) | RU2274643C2 (es) |
| SK (1) | SK13142003A3 (es) |
| WO (3) | WO2002085932A2 (es) |
| YU (1) | YU84103A (es) |
| ZA (3) | ZA200308274B (es) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040185061A1 (en) * | 1994-07-29 | 2004-09-23 | Innogenetics N.V. | Redox reversible HCV proteins with native-like conformation |
| WO2002085932A2 (en) * | 2001-04-24 | 2002-10-31 | Innogenetics N.V. | Constructs and methods for expression of recombinant hcv envelope proteins |
| DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
| AU2003283365A1 (en) * | 2002-11-08 | 2004-06-07 | Innogenetics N.V. | HCV vaccine compositions comprising E1 and NS3 peptides |
| US7439042B2 (en) * | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| JP4371739B2 (ja) * | 2003-09-02 | 2009-11-25 | 株式会社東芝 | シリアルａｔａインタフェースを持つ電子機器及びシリアルａｔａバスのパワーセーブ方法 |
| EP1574517A1 (en) * | 2004-03-09 | 2005-09-14 | Innogenetics N.V. | HCV E1 comprising specific disulfide bridges |
| EP1602664A1 (en) * | 2004-03-08 | 2005-12-07 | Innogenetics N.V. | HCV E1 comprising specific disulfide bridges |
| JP4885476B2 (ja) * | 2004-05-21 | 2012-02-29 | 株式会社日本触媒 | タンパク質及び／又はペプチドの細胞内導入方法 |
| AU2011254055B2 (en) * | 2004-10-18 | 2012-12-20 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| EP1809773B1 (en) * | 2004-10-18 | 2014-07-16 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis c infection |
| US20060234360A1 (en) * | 2005-04-13 | 2006-10-19 | Paola Branduardi | Ascorbic acid production from D-glucose in yeast |
| US9216212B2 (en) | 2005-08-05 | 2015-12-22 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| US7951384B2 (en) * | 2005-08-05 | 2011-05-31 | University Of Massachusetts | Virus-like particles as vaccines for paramyxovirus |
| PE20070796A1 (es) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
| CA2651456A1 (en) | 2006-05-19 | 2007-11-29 | Glycofi, Inc. | Recombinant vectors |
| AU2015234338C1 (en) * | 2006-07-28 | 2017-07-20 | The Trustees Of The University Of Pennsylvania | Improved vaccines and methods for using the same |
| EP2061805B1 (en) * | 2006-08-25 | 2020-02-12 | Macfarlane Burnet Institute for Medical Research and Public Health Limited | Recombinant hcv e2 glycoprotein |
| EP2331125A4 (en) | 2008-09-19 | 2013-03-27 | Globeimmune Inc | IMMUNOTHERAPY FOR CHRONIC HEPATITIS C-VIRUS INFECTIONS |
| WO2010039224A2 (en) | 2008-09-30 | 2010-04-08 | University Of Massachusetts Medical School | Respiratory syncytial virus (rsv) sequences for protein expression and vaccines |
| US20100104555A1 (en) * | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | HCV neutralizing epitopes |
| DE102009044224A1 (de) * | 2009-10-09 | 2011-04-28 | PomBio Tech GmbH Starterzentrum der Universität des Saarlandes Campus Geb. A1-1 | Methode zur Produktion von HCV Virus-ähnlichen Partikeln |
| DK2654785T3 (da) | 2010-12-22 | 2019-06-24 | Bayer Ip Gmbh | Forøget immunrespons hos kvægracer |
| US20140155469A1 (en) | 2011-04-19 | 2014-06-05 | The Research Foundation Of State University Of New York | Adeno-associated-virus rep sequences, vectors and viruses |
| US9534039B2 (en) | 2011-05-09 | 2017-01-03 | Ablynx N.V. | Method for the production of immunoglobulin single variable domains |
| MX2016010993A (es) * | 2014-02-28 | 2017-05-01 | Bayer Animal Health Gmbh | Plasmidos inmunoestimuladores. |
| JP2019504638A (ja) * | 2015-11-13 | 2019-02-21 | マメドフ、タルラン | Ｅｎｄｏ ｈとの同時発現によってインビボｎ−脱グルコシル化組換えタンパク質の産生 |
| EP3184642B1 (de) * | 2015-12-22 | 2019-05-08 | bisy e.U. | Hefezelle |
| AU2017332854A1 (en) | 2016-09-21 | 2019-04-11 | The Governors Of The University Of Alberta | Hepatitis C virus immunogenic compositions and methods of use thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4395395A (en) | 1979-05-21 | 1983-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of non-A, non-B hepatitis associated antigen |
| EP0288198A3 (en) * | 1987-04-20 | 1989-03-29 | Takeda Chemical Industries, Ltd. | Production of peptide |
| US5135854A (en) | 1987-10-29 | 1992-08-04 | Zymogenetics, Inc. | Methods of regulating protein glycosylation |
| US5683864A (en) | 1987-11-18 | 1997-11-04 | Chiron Corporation | Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies |
| US5350671A (en) | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
| US5698390A (en) | 1987-11-18 | 1997-12-16 | Chiron Corporation | Hepatitis C immunoassays |
| JP2791418B2 (ja) * | 1987-12-02 | 1998-08-27 | 株式会社ミドリ十字 | 異種蛋白質の製造方法、組換えｄｎａ、形質転換体 |
| NO177065C (no) * | 1988-09-26 | 1995-07-12 | Labofina Sa | Framgangsmåte for framstilling av enzymatisk aktivt humant lysozym |
| US5747239A (en) | 1990-02-16 | 1998-05-05 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines |
| US5712087A (en) | 1990-04-04 | 1998-01-27 | Chiron Corporation | Immunoassays for anti-HCV antibodies employing combinations of hepatitis C virus (HCV) antigens |
| WO1992001800A1 (en) * | 1990-07-20 | 1992-02-06 | Chiron Corporation | Method for integrative transformation of yeast using dispersed repetitive elements |
| CA2047792C (en) | 1990-07-26 | 2002-07-02 | Chang Y. Wang | Synthetic peptides specific for the detection of antibodies to hcv, diagnosis of hcv infection and prevention thereof as vaccines |
| ES2188583T3 (es) | 1991-06-24 | 2003-07-01 | Chiron Corp | Polipeptidos para el virus de la hepatitis c (hcv). |
| AU4659993A (en) | 1992-07-07 | 1994-01-31 | Merck & Co., Inc. | Vaccine comprising mixed pres1+pres2+s and core particle |
| DK0992580T3 (da) | 1993-11-04 | 2005-07-11 | Innogenetics Nv | Epitoper på human T-celler, som er immundominante for hepatitis C-virus |
| ES2174957T5 (es) * | 1994-07-29 | 2006-12-16 | Innogenetics N.V. | Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico. |
| ZA9610456B (en) * | 1995-12-20 | 1997-06-20 | Novo Nordisk As | N-terminally extended proteins expressed in yeast |
| US5935824A (en) * | 1996-01-31 | 1999-08-10 | Technologene, Inc. | Protein expression system |
| DE69735242T2 (de) * | 1996-12-20 | 2006-09-21 | Novo Nordisk A/S | N-terminal verlängerte proteine exprimiert in hefe |
| AU752131C (en) | 1997-11-06 | 2003-12-04 | Innogenetics N.V. | Multi-mer peptides derived from hepatitis C virus envelope proteins for diagnostic use and vaccination purposes |
| AU2149899A (en) * | 1998-01-23 | 1999-08-09 | Novo Nordisk A/S | Process for making desired polypeptides in yeast |
| TR200003024T2 (tr) | 1998-04-17 | 2000-12-21 | Innogenetics N.V. | İndirgeme ajanlarını kullanarak geliştirilen immünodiagnostik tahliller. |
| NZ508797A (en) * | 1998-06-24 | 2004-02-27 | Innogenetics N | Particles of HCV envelope proteins: use for vaccination |
| CA2387666A1 (en) | 1999-10-27 | 2001-05-03 | Innogenetics N.V. | Redox reversible hcv proteins with native-like conformation |
| WO2002055548A2 (en) | 2001-01-11 | 2002-07-18 | Innogenetics N.V. | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
| WO2002085932A2 (en) * | 2001-04-24 | 2002-10-31 | Innogenetics N.V. | Constructs and methods for expression of recombinant hcv envelope proteins |
| RU2319505C2 (ru) | 2001-12-18 | 2008-03-20 | Иннодженетикс Н.В. | Очищенные оболочечные белки вируса гепатита с для диагностического и терапевтического применения |
| AU2003283365A1 (en) | 2002-11-08 | 2004-06-07 | Innogenetics N.V. | HCV vaccine compositions comprising E1 and NS3 peptides |
-
2002
- 2002-04-24 WO PCT/BE2002/000062 patent/WO2002085932A2/en active IP Right Grant
- 2002-04-24 YU YU84103A patent/YU84103A/sh unknown
- 2002-04-24 BR BR0209034-1A patent/BR0209034A/pt not_active IP Right Cessation
- 2002-04-24 EP EP02764023A patent/EP1381671A2/en not_active Withdrawn
- 2002-04-24 RU RU2003130955/13A patent/RU2274643C2/ru not_active IP Right Cessation
- 2002-04-24 CA CA002443781A patent/CA2443781A1/en not_active Abandoned
- 2002-04-24 CA CA002443740A patent/CA2443740A1/en not_active Abandoned
- 2002-04-24 CZ CZ20032853A patent/CZ20032853A3/cs unknown
- 2002-04-24 JP JP2002583615A patent/JP4261195B2/ja not_active Expired - Fee Related
- 2002-04-24 AR ARP020101493A patent/AR035867A1/es unknown
- 2002-04-24 MX MXPA03009632A patent/MXPA03009632A/es not_active Application Discontinuation
- 2002-04-24 CN CNA028126076A patent/CN1636050A/zh active Pending
- 2002-04-24 NZ NZ529019A patent/NZ529019A/en unknown
- 2002-04-24 US US10/128,587 patent/US7314925B2/en not_active Expired - Fee Related
- 2002-04-24 AR ARP020101494A patent/AR035868A1/es unknown
- 2002-04-24 BR BR0209033-3A patent/BR0209033A/pt not_active IP Right Cessation
- 2002-04-24 EP EP02721875A patent/EP1414942A2/en not_active Withdrawn
- 2002-04-24 MX MXPA03009626A patent/MXPA03009626A/es not_active Application Discontinuation
- 2002-04-24 WO PCT/BE2002/000064 patent/WO2002086101A2/en active IP Right Grant
- 2002-04-24 OA OA1200500194A patent/OA13092A/en unknown
- 2002-04-24 AR ARP020101495A patent/AR035869A1/es unknown
- 2002-04-24 KR KR1020037013778A patent/KR100950104B1/ko not_active IP Right Cessation
- 2002-04-24 AU AU2002257392A patent/AU2002257392B2/en not_active Ceased
- 2002-04-24 WO PCT/BE2002/000063 patent/WO2002086100A2/en active Application Filing
- 2002-04-24 PL PL02366621A patent/PL366621A1/xx not_active Application Discontinuation
- 2002-04-24 AU AU2002252856A patent/AU2002252856A1/en not_active Abandoned
- 2002-04-24 AU AU2002308449A patent/AU2002308449B2/en not_active Ceased
- 2002-04-24 EP EP02727059A patent/EP1417298A2/en not_active Withdrawn
- 2002-04-24 NZ NZ529324A patent/NZ529324A/en unknown
- 2002-04-24 US US10/128,578 patent/US7048930B2/en not_active Expired - Fee Related
- 2002-04-24 US US10/128,590 patent/US7238356B2/en not_active Expired - Fee Related
- 2002-04-24 HU HU0303924A patent/HUP0303924A2/hu unknown
- 2002-04-24 JP JP2002583616A patent/JP4173741B2/ja not_active Expired - Fee Related
- 2002-04-24 SK SK1314-2003A patent/SK13142003A3/sk unknown
- 2002-04-24 CA CA002444006A patent/CA2444006A1/en not_active Abandoned
-
2003
- 2003-10-23 ZA ZA200308274A patent/ZA200308274B/en unknown
- 2003-10-23 ZA ZA200308272A patent/ZA200308272B/en unknown
- 2003-10-23 ZA ZA200308277A patent/ZA200308277B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035868A1 (es) | Un acido nucleico recombinante que codifica una proteina de un peptido lider de lisozima de ave o equivalente funcional, un vector que lo comprende, una celula huesped, un metodo para producir una proteina de envoltura del hcv o una parte de la misma. | |
| Carberry et al. | Analysis of major intracellular proteins of Aspergillus fumigatus by MALDI mass spectrometry: identification and characterisation of an elongation factor 1B protein with glutathione transferase activity | |
| DE69434083D1 (de) | Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird | |
| Gouveia et al. | Characterization of peroxisomal Pex5p from rat liver: Pex5p in the Pex5p-Pex14p membrane complex is a transmembrane protein | |
| WO2005017149A8 (en) | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site | |
| WO1999055868A3 (en) | Fizz proteins | |
| WO1998056927A3 (en) | Nucleic acids encoding polypeptide having protease activity | |
| Plietz et al. | Relationship between the amino acid sequence and the domain structure of the subunits of the 11S seed globulins | |
| BRPI0413501A (pt) | polipetìdeo, polinucleotìdeo isolado ou recombinante, vetor de expressão, célula hospedeira, e, método de preparar um polipetìdeo de hhdh | |
| WO2003052055A3 (en) | Egvii endoglucanase and nucleic acids encoding the same | |
| RU2009111842A (ru) | Фосфолипаза и способ ее получения | |
| DE69929886D1 (de) | Überexpression von phytase in hefesystemen | |
| Laurent et al. | Molecular cloning and partial characterization of a plant VAP33 homologue with a major sperm protein domain | |
| BR9713242A (pt) | Encapsulamento de polipeptìdeos dentro da matriz de amido | |
| WO2002046430A3 (en) | Improvement of homogeneity and secretion of recombinant proteins in mammalian systems | |
| ATE317443T1 (de) | N-terminal verlängerte proteine exprimiert in hefe | |
| AU5776799A (en) | Modified hcv peptide vaccines | |
| Kamei et al. | Phosphoproteome analysis of hereditary cataractous rat lens α-crystallin | |
| Moore et al. | Cytoskeletal proteins associated with cell surface envelopes from sarcoma 180 ascites tumor cells | |
| ATE254663T1 (de) | Erhöhte produktion von sekretierten proteinen durch rekombinante eukaryotische zellen | |
| ATE122099T1 (de) | Verfahren zur herstellung von c-terminalen alpha- amidierten peptiden. | |
| WO1999002708A8 (en) | Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein | |
| ES2111537T3 (es) | Inhibidor de la ribonucleasa de placenta humana recombinante y metodo de produccion. | |
| Hall et al. | Characterization of translation products of the polyadenylated RNA of free and membrane-bound polyribosomes of rat forebrain | |
| DE69025763D1 (de) | Vasodilatierende und immunsupprimierende peptide |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |